| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Osamu Yokota, Seishi Terada, Takeshi Ishihara, Hanae Nakashima, Aki Kugo, Hiroshi Ujike, Kuniaki Tsuchiya, Kenji Ikeda, Yuko Saito, Shigeo Murayama, Hideki Ishizu, Shigetoshi Kurod. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Progress in neuro-psychopharmacology & biological psychiatry. vol 28. issue 4. 2004-10-18. PMID:15276698. |
recently, a prospective double-blind study demonstrated that supplementary treatment with celecoxib, a selective cyclooxygenase-2 (cox-2) inhibitor, produced significantly greater improvement in scores on the positive and negative syndrome scale (panss) and on all subscales during the acute phase in patients with schizophrenia compared with risperidone alone therapy. |
2004-10-18 |
2023-08-12 |
Not clear |
| Robert A Lasser, Cynthia A Bossie, Young Zhu, Georges Gharabawi, Mariëlle Eerdekens, Michael Davidso. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. International journal of geriatric psychiatry. vol 19. issue 9. 2004-10-14. PMID:15352149. |
efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. |
2004-10-14 |
2023-08-12 |
Not clear |
| Chia-Yih Liu, Yeong-Yu Juang, Hsin-Yi Liang, Ni-Chi Lin, Eng-Kun Ye. Efficacy of risperidone in treating the hyperactive symptoms of delirium. International clinical psychopharmacology. vol 19. issue 3. 2004-10-06. PMID:15107660. |
the maximal daily dose of risperidone was in the range 0.5-4.0 mg, with a mean of 1.17+/-0.76 mg, which was much lower than that for schizophrenia. |
2004-10-06 |
2023-08-12 |
Not clear |
| Jonathan M Meyer, Susan G Leckband, Catherine Loh, Christine Y Moutie. Quetiapine-induced diabetes with metabolic acidosis. International clinical psychopharmacology. vol 19. issue 3. 2004-10-06. PMID:15107661. |
presented here is the case of a 51 year old male with schizophrenia who developed retrograde ejaculation on high dose risperidone therapy (8 mg/day) with prompt resolution of symptoms upon dose reduction. |
2004-10-06 |
2023-08-12 |
Not clear |
| C Lindsay DeVane, Jacob Mintze. Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update. Psychopharmacology bulletin. vol 37. issue 4. 2004-09-28. PMID:15131522. |
published data from controlled and uncontrolled trials in elderly patients support the efficacy of risperidone in controlling behavioral and psychological symptoms of dementia, as well as treating psychotic symptoms associated with schizophrenia and other disorders with psychotic features. |
2004-09-28 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Els Eerdekens, Sally A Berry, Mariëlle Eerdeken. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. The Journal of clinical psychiatry. vol 65. issue 8. 2004-09-21. PMID:15323593. |
safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. |
2004-09-21 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Els Eerdekens, Sally A Berry, Mariëlle Eerdeken. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. The Journal of clinical psychiatry. vol 65. issue 8. 2004-09-21. PMID:15323593. |
the safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications. |
2004-09-21 |
2023-08-12 |
Not clear |
| W Ukai, H Ozawa, M Tateno, E Hashimoto, T Sait. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. Journal of neural transmission (Vienna, Austria : 1996). vol 111. issue 6. 2004-09-14. PMID:15168214. |
haloperidol but not risperidone induces caspase-dependent apoptosis by reducing cellular survival signaling, which possibly contributes to the differential clinical therapeutic efficacy and expression of side effects in schizophrenia. |
2004-09-14 |
2023-08-12 |
rat |
| Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Pei Yan Zhang, Gui Ying Wu, Yu Cun She. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. The Journal of clinical psychiatry. vol 65. issue 7. 2004-09-13. PMID:15291683. |
changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. |
2004-09-13 |
2023-08-12 |
Not clear |
| Michael A Reveley, Susan E Librett. Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. Journal of clinical psychopharmacology. vol 24. issue 3. 2004-09-07. PMID:15118479. |
treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. |
2004-09-07 |
2023-08-12 |
Not clear |
| Michael A Reveley, Susan E Librett. Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. Journal of clinical psychopharmacology. vol 24. issue 3. 2004-09-07. PMID:15118479. |
treatment outcome was evaluated in outpatients with chronic schizophrenia during long-term administration of risperidone in a study reflecting clinical practice. |
2004-09-07 |
2023-08-12 |
Not clear |
| Michael A Reveley, Susan E Librett. Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. Journal of clinical psychopharmacology. vol 24. issue 3. 2004-09-07. PMID:15118479. |
after 1 year of risperidone treatment in a naturalistic setting reflecting usual uk clinical practice, patients with chronic schizophrenia showed improvement in symptoms and reduction in disease severity, and only 10 of 79 had relapse; 48.1% of patients were considered to be sustained treatment successes, 36.7% as treatment failures, and 15.2% as not "evaluable." |
2004-09-07 |
2023-08-12 |
Not clear |
| Thomas J Raedler, Andreas Schreiner, Dieter Naber, Klaus Wiedeman. Risperidone in the treatment of acute schizophrenia. Journal of clinical psychopharmacology. vol 24. issue 3. 2004-09-07. PMID:15118488. |
risperidone in the treatment of acute schizophrenia. |
2004-09-07 |
2023-08-12 |
Not clear |
| Chiao-Li Ke, Cheng-Fang Yen, Cheng-Chung Chen, Shang-Ju Yang, Weilun Chung, Ming-Jen Yan. Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature. The Kaohsiung journal of medical sciences. vol 20. issue 6. 2004-08-31. PMID:15253471. |
we present three cases of schizophrenia in which distressing ocss occurred during clozapine or risperidone treatment. |
2004-08-31 |
2023-08-12 |
Not clear |
| Y Yamanouchi, N Iwata, T Suzuki, T Kitajima, M Ikeda, N Ozak. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. vol 3. issue 6. 2004-08-09. PMID:14610521. |
in all, 73 japanese patients with schizophrenia were given risperidone for 8 weeks, and clinical symptoms were evaluated using the positive and negative syndrome scale (panss). |
2004-08-09 |
2023-08-12 |
Not clear |
| Tony Vangeneugden, Annouschka Laenen, Helena Geys, Didier Renard, Geert Molenbergh. Applying linear mixed models to estimate reliability in clinical trial data with repeated measurements. Controlled clinical trials. vol 25. issue 1. 2004-08-09. PMID:14980746. |
the methodology is motivated by and applied to data from five double-blind randomized clinical trials comparing the effects of risperidone to conventional antipsychotic agents for the treatment of chronic schizophrenia. |
2004-08-09 |
2023-08-12 |
Not clear |
| Rajiv Tando. Risperidone improves severe tardive dyskinesia in people with schizophrenia. Evidence-based mental health. vol 7. issue 3. 2004-08-05. PMID:15273227. |
risperidone improves severe tardive dyskinesia in people with schizophrenia. |
2004-08-05 |
2023-08-12 |
Not clear |
| Leslie Citrom. Schizophrenia and valproate. Psychopharmacology bulletin. vol 37 Suppl 2. 2004-08-03. PMID:15021863. |
a recently completed 28-day, double-blind, randomized clinical trial of 249 patients with schizophrenia demonstrated faster improvement in psychopathology with a combination therapy of divalproex and risperidone or olanzapine, compared to monotherapy with risperidone or olanzapine. |
2004-08-03 |
2023-08-12 |
Not clear |
| Susan R McGurk, Michael F Green, William C Wirshing, Donna Ames Wirshing, Steven R Marder, Jim Mintz, Robert Ker. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophrenia research. vol 68. issue 2-3. 2004-07-23. PMID:15099605. |
the effects of haloperidol and risperidone on these two types of spatial memory were evaluated in a double-blind randomized comparison in inpatients with schizophrenia. |
2004-07-23 |
2023-08-12 |
human |
| Philip J Tyson, Kate H Roberts, Ann M Mortime. Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? The International journal of neuroscience. vol 114. issue 6. 2004-07-19. PMID:15204055. |
forty-four patients with a dsm-iv diagnosis of schizophrenia were recruited within 6 weeks of starting one of the atypical antipsychotics: clozapine, olanzapine, risperidone, quetiapine, or amisulpride. |
2004-07-19 |
2023-08-12 |
Not clear |